Research Study

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
Principal Investigator 
Martin Gleave

Overview

Body Locations and Systems 
ClinicalTrials.gov# 
NCT03767244
Status 
Recruiting
Study Start/End 
Aug 6, 2019 to Dec 28, 2027
Locations 
Diamond Health Care Centre
Name/Title 
Jonathan Ma, Research Coordinator
Email Address 
jma@prostatecentre.com
Purpose of Study 

The purpose of this study is to determine if treatment with androgen deprivation therapy (ADT) plus apalutamide before and after radical prostatectomy in participants with high-risk localized or locally advanced prostate cancer results in an improvement in pathological complete response (pCR) rate and metastasis-free survival (MFS), as compared to ADT plus placebo.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.